What is driving the pre-market volume spike in GV.PA stock?

Pre-market volume for GV.PA stock rose due to short-term liquidity trades and heightened interest from active traders. Reported volume is **38.49M**, about **2.71x** the average, which typically reflects speculative flows, news scans or block orders rather than improved fundamentals.

How does Meyka AI view GV.PA stock and its forecast?

Meyka AI rates GV.PA with a score out of 100 at **58.71** (Grade C+, Suggestion: HOLD). Meyka AI's forecast model projects **€0.0100** in 12 months versus current **€0.0018**. Forecasts are model-based projections and not guarantees.

What are the main financial risks for investors in GV.PA stock?

Major risks include negative EPS (**-0.11**), negative book value per share, limited cash per share (**€0.00557**), and a current ratio below **1.0**. These metrics indicate potential funding pressure and high dilution or restructuring risk.

EU Stocks

GV.PA Genomic Vision SA EURONEXT pre-market 15 Jan 2026: 38.49M shares at €0.0018, watch liquidity

ByHuzaifa Zahoor January 15, 2026January 15, 2026

GV.PA stock is the most active name in pre-market trading on EURONEXT on 15 Jan 2026, with 38.49M shares changing hands and a quoted price of €0.0018. Volume today is about 2.71x the average, pushing liquidity to the top of traders’ watch lists. Intraday range sits near €0.0015–€0.0020, while the company remains a micro-cap in the Healthcare diagnostics sector. We examine trading drivers, valuation, balance sheet metrics and a model forecast to frame risk and opportunity for short-term and strategic investors.